C-Jun N-terminal kinase (JNK)-phospho-c-JUN (ser63/73) pathway is essential for FOXP3 nuclear translocation in psoriasis

Journal of Dermatological Science

Volumn 69, Issue 2, 2013, Pages 114-121

  Chen, Ling ^a   Wu, Jinjin ^a   Ren, Wenying ^b   Yang, Xichuan ^c   Shen, Zhu ^c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b TUFTS MEDICAL CENTER   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

C JUN; FOXP3; JNK; Nuclear; Psoriasis

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASMIC RETENTION; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; REGULATORY T LYMPHOCYTE; ULTRAVIOLET B RADIATION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ADOLESCENT; ADULT; AGED; ANTHRACENES; CELL NUCLEUS; CHILD; CYTOPLASM; ENZYME INHIBITORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-17; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PHOSPHORYLATION; PSORIASIS; T-LYMPHOCYTES, REGULATORY; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 84873571307     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.10.018     Document Type: Article

References (38)

1. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007, 56:629-634.
2. Alexandroff A.B., Pauriah M., Camp R.D., Lang C.C., Struthers A.D., Armstrong D.J. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161:1-7.
3. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
4. Chen L., Shen Z., Wang G., Fan P., Liu Y. Dynamic frequency of CD4+CD25+FOXP3+ Treg cells in psoriasis vulgaris. J Dermatol Sci 2008, 51:200-203.
5. Shen Z., Chen L., Hao F., Wu J. Transcriptional regulation of FOXP3 gene: multiple signal pathways on the road. Med Res Rev 2009, 29:742-766.
6. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
7. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
8. Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., et al. FOXP3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
9. Wu Y., Borde M., Heissmeyer V., Feurer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
10. Lopes J.E., Torgerson T.R., Schubert L.A., Anover S.D., Ocheltree E.L., Ochs H.D., et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol 2006, 177:3133-3142.
11. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.
12. Karanikas V., Speletas M., Zamanakou M., Kalala F., Loules G., Kerenidi T., et al. FOXP3 expression in human cancer cells. J Transl Med 2008, 6:19.
13. Chen L., Shen Z., Wu J. Effects of ultraviolet radiation exposure on FOXP3+ infiltration in cutaneous squamous cell carcinoma and basal cell carcinoma. Photodermatol Photoimmunol Photomed 2011, 27:297-303.
14. Ladoire S., Arnould L., Mignot G., Coudert B., Rćbć C., Chalmin F., et al. Presence of FOXP3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 125:65-72.
15. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Hdson-Eredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
16. Tanemura S., Momose H., Shimizu N., Kitagawa D., Seo J., Yamasaki T., et al. Blockage by SP600125 of Fcepsilon receptor-induced degranulation and cytokine gene expression in mast cells is mediated through inhibition of phosphatidylinositol 3-kinase signalling pathway. J Biochem 2009, 145:345-354.
17. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007, 408:297-315.
18. Lapolla W., Yentzer B.A., Bagel J., Halvorson C.R., Feldman S.R. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011, 64:936-949.
19. Søyland E., Heier I., Rodríguez-Gallego C., Mollnes T.E., Johansen F.E., Holven K.B., et al. Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. Br J Dermatol 2011, 164:344-355.
20. Saito C., Maeda A., Morita A. Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis. J Dermatol Sci 2009, 53:231-233.
21. Meng Q., Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell 2011, 2:889-898.
22. Kaneto H., Matsuoka T.A., Katakami N., Kawamori D., Miyatsuka T., Yoshiuchi K., et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 2007, 7:674-686.
23. de Launay D., van de Sande M.G., de Hair M.J., Grabiec A.M., van de Sande G.P., Lehmann K.A., et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis 2012, 71:415-423.
24. Melino M., Hii C.S., McColl S.R., Ferrante A. The effect of the JNK inhibitor JIP peptide, on human T lymphocyte proliferation and cytokine production. J Immunol 2008, 181:7300-7306.
25. Dong C., Yang D.D., Tournier C., Whitmarsh A.J., Xu J., Davis R.J., et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000, 405:91-94.
26. Dong C., Yang D.D., Wysk M., Whitmarsh A.J., Davis R.J., Flavel R.A. Defective T cell differentiation in the absence of JNK1. Science 1998, 282:2092-2095.
27. Peus D., Beyerle A., Rittner H.L., Pott M., Meves A., Weyand C., et al. Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes. J Invest Dermatol 2000, 114:688-692.
28. Joetham A., Ohnishi H., Okamoto M., Takeda K., Schedel M., Domenico J., et al. Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation. J Biol Chem 2012, 287:17100-17108.
29. Li L., Kim J., Boussiotis V.A. IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol 2010, 185:4148-4153.
30. Hasegawa H., Lei J., Matsumoto T., Onishi S., Sumori K., Yasukawa M. Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun 2011, 415:526-531.
31. Liu Y., Wang Y., Li W., Zheng P., Liu Y. Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Res 2009, 69:5954-5960.
32. Ishimaru N., Yamada A., Nitta T., Arakaki R., Lipp M., Takahama Y., et al. CCR7 with S1P1 signaling through AP-1 for migration of Foxp3+ regulatory T-cells controls autoimmune exocrinopathy. Am J Pathol 2012, 180:199-208.
33. Gazel A., Banno T., Walsh R., Blumenberg M. Inhibition of JNK promotes differentiation of epidermal keratinocytes. J Biol Chem 2006, 281:20530-20541.
34. Johansen C., Kragballe K., Westergaard M., Henningsen J., Kristiansen K., Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005, 152:37-42.
35. Takahashi H., Ibe M., Nakamura S., Ishida-Yamamoto A., Hashimoto Y., Iizuka H. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002, 30:94-99.
36. 2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med 2001, 193:317-328.
37. Blonska M., Lin X. CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev 2009, 228:199-211.
38. Guma M., Ronacher L.M., Firestein G.S., Karin M., Karr M. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum 2011, 63:1603-1612.